FB74R2c4, CENSOi261
CENSOi002-B
General
Cell Line |
|
| hPSCreg name | CENSOi002-B |
| Cite as: | CENSOi002-B (RRID:CVCL_LE87) |
| Alternative name(s) |
FB74R2c4, CENSOi261
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CENSOi003-B (FB79R2c6, CENSOi258) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi005-A (FB76R2c5, CENSOi245) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi007-A (FB75R2c5, CENSOi255) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi001-B (FB78R2c2, CENSOi249) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi008-A (FB77R2c3, CENSOi260) Donor's gene variants: DMPK, DMPK Donor diseases: myotonic dystrophy type 1 RCi009-A (Rci201, FB73c6) Donor's gene variants: LRIF1, LRIF1 Donor diseases: Facioscapulohumeral dystrophy RCi006-A (FB69c4, RCi169) Donor's gene variants: LRIF1, LRIF1 Donor diseases: Facioscapulohumeral dystrophy RCi007-A (FB70c1, RCi170) Donor's gene variants: LRIF1, LRIF1 Donor diseases: Facioscapulohumeral dystrophy STBCi110-A (SFC116-03-01) Donor's gene variants: CFH Donor diseases: type 2 diabetes mellitus age-related macular degeneration |
| Last update | 14th May 2022 |
| User feedback | |
Provider |
|
| Generator | Censo an Axol Bioscience Company (CENSO) |
| Distributors | |
External Databases |
|
| BioSamples | SAMEA104133811 |
| Cellosaurus | CVCL_LE87 |
| Wikidata | Q54809294 |
General Information |
|
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 5-9 |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA104386350 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project | research area restriction to Neuromuscular Research |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Does consent permit access to medical records of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | The London -West London & GTAC Research Ethics Committee |
| Approval number | |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | The London -West London & GTAC Research Ethics Committee |
| Approval number | |
| Do you have obligations to third parties in regard to the use of the cell line? | Yes |
| Please describe: | research area restriction to Neuromuscular Research |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell type |
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative.
|
| Age of donor (at collection) | 5-9 |
Reprogramming method |
|
| Vector type | None |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
mRNA
|
| mRNA | |
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| TRA 1-60 |
Yes |
|
||||
| SSEA-1 |
No |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| SSEA-4 |
Yes |
|
Differentiation Potency
In vitro spontaneous differentiation
In vitro directed differentiation
In vitro spontaneous differentiation
In vitro directed differentiation
In vitro spontaneous differentiation
In vitro directed differentiation
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
9
|
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
No autosomal or sex chromosome aneuploidies were detected
Passage number: 9
Karyotyping method:
KaryoLite BoBs
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.